Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

10.1%

35 terminated/withdrawn out of 345 trials

Success Rate

89.1%

+2.6% vs industry average

Late-Stage Pipeline

50%

171 trials in Phase 3/4

Results Transparency

48%

138 of 286 completed trials have results

Key Signals

8 recruiting138 with results26 terminated9 withdrawn

Enrollment Performance

Analytics

Phase 3
120(39.7%)
Phase 2
74(24.5%)
Phase 4
51(16.9%)
Phase 1
36(11.9%)
N/A
21(7.0%)
302Total
Phase 3(120)
Phase 2(74)
Phase 4(51)
Phase 1(36)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (345)

Showing 20 of 345 trials
NCT04115566Recruiting

Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository

Role: collaborator

NCT07555171Enrolling By Invitation

EEG Dynamics in Lennox-Gastaut Syndrome Patients Undergoing Fenfluramine Treatment

Role: collaborator

NCT06336343Phase 4Completed

Bimekizumab in Plaque Psoriasis

Role: collaborator

NCT07215949Phase 3Recruiting

Zilucoplan for Severe gMG Exacerbations

Role: collaborator

NCT07033559Not Yet Recruiting

Detecting Fatigue From Voice in Generalised Myasthenia Gravis

Role: collaborator

NCT04179695Not ApplicableRecruiting

Evaluation of a New Communication Aid Tool to Favor Global Patient Centered Care

Role: collaborator

NCT07225231Not ApplicableNot Yet Recruiting

Clinical Utility of Reduced EEG Home Monitoring in Fenfluramine Titration for Dravet and LGS

Role: collaborator

NCT01793103Active Not Recruiting

Brigham and Women's Rheumatoid Arthritis Sequential Study

Role: collaborator

NCT06754098Phase 2Recruiting

Doxecitin and Doxribthymine in Adult Subjects With Thymidine Kinase 2 (TK2) Deficiency

Role: collaborator

NCT06381284Completed

Expediting Myasthenia Gravis (MG) Diagnostic Evaluation: A Novel, Proof-of-Concept for Undiagnosed, Symptomatic Patients That Uses Social Media Targeting and Self-Assessment

Role: collaborator

NCT04985539Active Not Recruiting

The Personalized Parkinson Project De Novo Cohort

Role: collaborator

NCT05501431Completed

Personalized Parkinson Project PSP Cohort

Role: collaborator

NCT06866483Recruiting

Validation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired With a Self-moderated Assessment

Role: collaborator

NCT01797224Active Not Recruiting

OTIS Cimzia Pregnancy Registry

Role: collaborator

NCT01848028Recruiting

PsoBest - The German Psoriasis Registry

Role: collaborator

NCT06598449Phase 4Recruiting

Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of Age

Role: collaborator

NCT01009242Phase 1Completed

To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate

Role: lead

NCT01242488Phase 2Completed

Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

Role: lead

NCT02451748Phase 4Completed

IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA

Role: collaborator

NCT03489044Phase 2Completed

An Investigation of Levetiracetam in Alzheimer's Disease

Role: collaborator